Quantcast

Latest Insulin therapy Stories

2014-04-07 23:22:26

GIA announces the release of a comprehensive global report on Insulin Pumps (External) markets. Global market for Insulin Pumps (External) is forecast to reach US$1.7 billion by 2020, buoyed by rising obesity, high prevalence of diabetes, and the subsequent need to improve diabetes management. San Jose, California (PRWEB) April 07, 2014 Follow us on LinkedIn – Insulin Pump therapy, also known as Continuous Subcutaneous Insulin Infusion (CSII) therapy, has gained prominence over the...

2014-04-04 23:29:56

MannKind's AFREZZA takes a big step towards FDA approval. Princeton, NJ (PRWEB) April 03, 2014 PharmApprove, the leading strategic, regulatory, and scientific communications consultancy to the pharmaceutical and biotech industries, congratulates client MannKind Corporation on its successful U.S. Food and Drug Administration (FDA) Endocrine and Metabolic Advisory Committee meeting this week. The committee voted 13 to 1 on April 1 to recommend that MannKind’s AFREZZA® (insulin...

2014-03-27 08:34:50

JERUSALEM, March 27, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the first patient has been enrolled in its U.S. Phase 2a trial for its orally ingestible insulin capsule, ORMD-0801, in the treatment of type 1 diabetes (T1DM). "We are pleased to be initiating this U.S. clinical trial with ORMD-0801 in...

2014-03-26 10:55:43

A study published in Diabetologia (the journal of the European Association for the Study of Diabetes) is the first to provide direct evidence that fetal brain response to a dose of sugar given orally to its mother is associated with the mother's insulin sensitivity. This may indicate that the risk of subsequent obesity and diabetes may be pre-programmed in the womb. The study is by Dr Hubert Preissl and Dr Andreas Fritsche, University of Tübingen, Germany and German Center for Diabetes...

2014-03-05 12:26:53

- Study showed ease-of-use, efficacy and high satisfaction among participants who transitioned from multiple daily insulin injections to PaQ device - HORW, Switzerland, March 5, 2014 /PRNewswire/ -- CeQur(®) SA, a company focused on the development and commercialization of simple insulin delivery devices, announced that comprehensive results from a clinical study of the company's PaQ(® )Insulin Delivery Device were published online today in Diabetes Care, a peer-reviewed journal...

2014-02-11 08:30:24

Research advances in novel pathways produce innovative antidiabetic drugs, which will pave the way for successful market penetration LONDON, Feb. 11, 2014 /PRNewswire/ -- Type 2 diabetes is one of the most significant global health concerns of modern times. According to the International Diabetes Federation, more than 55 million people have been diagnosed with diabetes in Europe in 2012, and this number is expected to rise to 64 million by 2030. A recent research by Frost &...

2014-02-07 13:00:08

Insulin use to treat type 2 diabetes trebles over 20 years "Understanding the pattern of insulin use is limited by a lack of data characterizing the prevalence of insulin use in the UK," according to Craig Currie, Professor of Applied Pharmacoepidemiology at Cardiff University's School of Medicine, who led the study alongside colleagues from the University of Bristol. "Given the limitations, our study sought to calculate – for the first time – the best possible estimate of the rates...

2014-01-31 12:25:16

INDIANAPOLIS, Jan. 31, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has provided the following statement regarding a lawsuit filed by Sanofi in the United States District Court for the District of Delaware alleging patent infringement with respect to LY2963016, a new insulin glargine product for which Lilly is currently seeking approval from the U.S. Food and Drug Administration (FDA). "Lilly respects the intellectual property of others and does not believe the...

2014-01-22 23:21:43

London, Ontario-based Sernova Corp., is developing a better way to treat the disease involving the replacement of lost pancreatic islets, whose function is to read blood sugar levels and release insulin into the blood, normalizing blood sugar levels. London, ON (PRWEB) January 22, 2014 Imagine there is a person with diabetes who must focus on measuring their blood sugar levels almost constantly followed by injection of insulin multiple times each day or monitoring their insulin pump...

2014-01-08 08:28:16

HORW, Switzerland, Jan. 8, 2014 /PRNewswire/ -- CeQur(®) SA, a leader in simple insulin infusion for people with type 2 diabetes, today announced that the company has been invited to present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco. CeQur management is scheduled to present an overview of the company at the Westin St. Francis Hotel on Wednesday, 15 January, 2014 at 7:30 a.m. PT. The Need for Simple Insulin InfusionThere are currently more than 11 million...


Latest Insulin therapy Reference Libraries

0_0d961f30bdfa64859d9b869b063ddcd2
2010-12-03 18:12:26

Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...

More Articles (1 articles) »
Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related